A carregar...
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia
BACKGROUND: Benign prostatic hyperplasia (BPH) refers to non‐malignant enlargement of the prostate gland that may cause bothersome lower urinary tract symptoms (LUTS). Alpha‐blockers (ABs) and 5‐alpha reductase inhibitors (5‐ARIs) are the mainstay of medical treatment. Recently, phosphodiesterase in...
Na minha lista:
| Publicado no: | Cochrane Database Syst Rev |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Ltd
2018
|
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6517182/ https://ncbi.nlm.nih.gov/pubmed/30480763 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD010060.pub2 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|